Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Policy Prescriptions: User Fees, EMA Worries, PBM Strategies, PRIME Milestones

Executive Summary

The US has plenty of new pharma legislation, Europe has plenty of worries about EMA's Brexit move, pharmacy benefit managers give plenty more scrutiny to which products earn a place on formulary. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Advertisement

Related Content

Bids For EMA Show East-West Split Over Principle of Fair Spread Of Agencies
Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House
Not Quite FDARA Add-Ons: Right-To-Try, Patient Experience, Opioid Measures Also Clear US Senate
Irish Regulator Prepares For Brexit-Related Problems, Offers To Take On More EU Work
CVS 2018 Formulary: Outcomes-Based Contracts In Oncology, Obesity, COPD
EMA Consults On Integrating Needs Of Older People Into Drug Development
EU Firsts For CAR-T & PRIME As EMA Grants Kite Accelerated Assessment
Express Scripts Boosts Formulary Exclusions With Focus On Multi-Source Brands
Pharma And Health Reform: Staying On The Sidelines Works Out
EMA Plans Guidance To ‘Closely Knit’ Development Of Companion Diagnostics And Drugs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel